Yahoo India Web Search

Sign In

Search results

  1. www.trials.mirati.com › about › faqMirati Trials

    mirati@careboxhealth.com Our Clinical Trial Navigators* can help you find a match, connect with a site or join our registry to receive updates. Monday - Friday 9:00 am - 6:00 pm ET

  2. www.trials.mirati.com › condition › solid-tumor-cancersMirati Trials - Bristol Myers Squibb

    Mirati is dedicated to discovering treatment options that target genetically-defined solid tumor cancers such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, mesothelioma, malignant neoplastic disease, malignant peripheral nerve sheath tumors, and adenocarcinoma.

  3. trials.mirati.com › questionnaire › diseasesMirati Trials - Bristol Myers Squibb

    Answer a few questions to find which Mirati trials may be the best fit for you or your loved one. When you press “Start Questionnaire” , you will be presented with a few questions about your or the patient’s condition and treatment history.

  4. www.mirati.com › science › clinical-trialsClinical Trials | Mirati Therapeutics, Inc. - Bristol Myers...

    Mirati is now a Bristol Myers Squibb company. Select Accept for Information about Mirati. To learn more about Bristol Myers Squibb

  5. trials.mirati.com › trial › listingPhase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in...

    May 16, 2024 · mirati@careboxhealth.com Our Clinical Trial Navigators* can help you find a match, connect with a site or join our registry to receive updates. Monday - Friday 9:00 am - 6:00 pm ET

  6. www.trials.mirati.com › about › genetic-mutationsMirati Trials - Bristol Myers Squibb

    mirati@careboxhealth.com Our Clinical Trial Navigators* can help you find a match, connect with a site or join our registry to receive updates. Monday - Friday 9:00 am - 6:00 pm ET

  7. www.trials.mirati.com › condition › colorectal-cancerMirati Trials

    Below is one of Mirati’s ongoing clinical trials in colorectal cancer. KRYSTAL-10: A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

  8. www.trials.mirati.com › condition › non-small-cell-lung-cancerMirati Trials

    Below are Mirati’s ongoing clinical trials in non-small cell lung cancer. KRYSTAL-1: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

  9. www.trials.mirati.com › condition › pancreatic-cancerMirati Trials - Bristol Myers Squibb

    Below are Mirati’s ongoing clinical trials in pancreatic cancer. KRYSTAL-1: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation Medicines

  10. www.mirati.com › wp-content › uploadsIdentification of Mechanism-based Combination Targets Effective...

    Mirati Therapeutics, Inc., San Diego, CA 92121, USA; 2. Monoceros Biosystems LLC, San Diego, CA 92172, USA MRTX1719 is an MTA cooperative PRMT5 inhibitor that preferentially binds to the PRMT5•MTA complex, leveraging the increased MTA concentration associated with. MTAP . deletion to selectively target . MTAP. del cancer cells. MTAP